ARTICLE

Received 17 Jun 2014 | Accepted 15 Dec 2014 | Published 6 Feb 2015

DOI: 10.1038/ncomms7129

Structural mechanism of ergosterol regulation by fungal sterol transcription factor Upc2

Huiseon Yang¹, Junsen Tong¹, Chul Won Lee², Subin Ha¹, Soo Hyun Eom³ & Young Jun Im¹

Transcriptional regulation of ergosterol biosynthesis in fungi is crucial for sterol homeostasis and for resistance to azole drugs. In *Saccharomyces cerevisiae*, the Upc2 transcription factor activates the expression of related genes in response to sterol depletion by poorly understood mechanisms. We have determined the structure of the C-terminal domain (CTD) of Upc2, which displays a novel α -helical fold with a deep hydrophobic pocket. We discovered that the conserved CTD is a ligand-binding domain and senses the ergosterol level in the cell. Ergosterol binding represses its transcription activity, while dissociation of the ligand leads to relocalization of Upc2 from cytosol to nucleus for transcriptional activation. The C-terminal activation loop is essential for ligand binding and for transcriptional regulation. Our findings highlight that Upc2 represents a novel class of fungal zinc cluster transcription factors, which can serve as a target for the developments of antifungal therapeutics.

¹ College of Pharmacy, Chonnam National University, Gwangju 500-757, South Korea. ² Department of Chemistry, Chonnam National University, Gwangju 500-757, South Korea. ³ School of Life Science, Steitz Center for Structural Biology, and Department of Chemistry, Gwangju Institute of Science and Technology, Gwangju 500-712, South Korea. Correspondence and requests for materials should be addressed to Y.J.I. (email: imyoungjun@jnu.ac.kr).

Ergosterol is the major fungal membrane sterol that regulates membrane fluidity, plasma membrane biogenesis and function¹. Ergosterol homeostasis is critical for fungal cells. Part of this regulation involves the transcription control of genes encoding ergosterol biosynthetic enzymes and proteins that perform sterol processing and uptake². In some fungal species, such as *Schizosaccharomyces pombe*, it is mediated by hypoxic regulatory proteins, Sre1 and Scp1, which share common features with the mammalian sterol regulatory element-binding proteins (SREBPs) and SREBP cleavage-activating protein^{3,4}. However, many other fungal species, including *Saccharomyces cerevisiae* and *Candida* species, lack protein homologues of the mammalian cholesterol regulators and appear to have evolved distinct regulatory mechanism⁵. In *S. cerevisiae*, Upc2 and Ecm22, two similar zinc finger transcriptional factors, have been implicated in ergosterol regulation by binding to the promoters of ergosterol biosynthetic and sterol uptake genes and activating the transcription on sterol depletion^{2,6}. In addition, *S. cerevisiae* Upc2 is important for adaptation to hypoxia regulating up to one-third of anaerobically expressed genes⁷. Upc2 contains an amino-terminal (N-terminal) DNA-binding domain characterized by a conserved Zn(II)₂-Cys₆ zinc finger motif and a carboxyl-terminal (C-terminal) conserved domain of unknown function.

Owing to the essential role of ergosterol in fungal membranes, azole drugs that inhibit ergosterol biosynthesis are widely used for the treatment of fungal infections. *Candida albicans* is responsible for a large proportion of infections in immunocompromised individuals and the emergence of drug-resistant strains is of medical concern⁸. Resistance to azole drugs is partly due to the alteration of the ergosterol biosynthetic pathway. Many gain-of-function mutations in Upc2 that contribute to the drug resistance were identified in clinical isolates⁸. Mutations in the C-terminal domain (CTD) of Upc2 (A643V, A643T or G648D in *C. albicans* Upc2) result in the constitutive activation of the transcription factor (TF), resulting in the upregulation of ergosterol synthesis pathway and sterol uptake, which leads to a decreased susceptibility of the strains to azole drugs^{9,10}. The gain-of-function mutation, G888D, in *S. cerevisiae* Upc2 results in the constitutive activation of the TF with a high level of aerobic sterol uptake^{11,12}. These constitutive activation mutations are in close proximity in the C-terminal portion of Upc2, which may indicate that the CTD is important for the regulation of its transcriptional activity⁹. The CTDs of Upc2 and Ecm22 have no recognizable similarities to any characterized protein domains of known structures. However, conservation of this region across a large number of zinc TFs in many fungal species indicates that the CTD may represent a novel domain¹³. Deletion of *UPC2* in pathogenic fungi, *C. albicans* and *C. glabrata*, leads to a significant decrease of tolerance to azole drugs and deletion of both *UPC2* and *ECM22* in *S. cerevisiae* is lethal in certain yeast

strains^{6,14,15}. Therefore, the Upc2 pathway may represent a potential co-therapeutic target for enhancing azole activity against these organisms¹⁶.

Nuclear receptors (NRs) are soluble proteins that can bind to specific DNA-regulatory elements and acts as promotor-specific regulators of transcription. The activity of most NRs is modulated by binding of small lipophilic molecules¹⁷. Recent studies proposed that several members of the fungal zinc cluster family of transcription regulators may represent functional analogues of metazoan NRs¹³. Transcriptional activity of Oaf1/Pip2 is regulated by oleate binding to the CTD with similar ligand-binding characteristics and coactivator requirements to mammalian PPAR/RXR receptors^{18,19}. Pdr1 zinc TFs bind to diverse xenobiotics and stimulate expression of drug efflux pumps resulting in induction of multidrug resistance in *S. cerevisiae* and *C. glabrata*, which is functionally similar to the regulation of multidrug resistance in vertebrates by the PXR NR^{19,20}. However, due to the lack of structural and biochemical information of the fungal zinc finger transcriptional factors, the characteristics of this gene family have remained elusive.

In this study, we have determined the crystal structure of the CTD of Upc2 from *S. cerevisiae*. We discovered that the CTD of Upc2 is a ligand-binding domain (LBD) for fungal sterols that regulate the transcriptional activity and cellular localization of Upc2 in a ligand-dependent manner. Upc2 displays conceptual similarities in domain architectures and the regulation of transcription activity to mammalian NRs. However, Upc2 LBD displays a distinct structural fold compared with the LBDs of metazoan NRs suggesting that Upc2 represents a novel class of zinc finger TFs. This study reveals that fungal zinc cluster TFs might be suitable targets for the developments of small drugs that could aid current antifungal therapy.

Results

Upc2 is a specific receptor for ergosterol. Upc2 and Ecm22 share a high level of sequence similarity in the N-terminal DNA-binding domains characterized by a conserved Zn(II)₂-Cys₆ zinc finger motif²¹. The C-terminal conserved region of about 300 amino-acid residues contains a transcription activation domain (Fig. 1a). Since the transcriptional activity of Upc2 is dependent on ergosterol levels in the cell, we hypothesized that the CTD may serve as a LBD for ergosterol and regulate transcriptional activity of Upc2. Dehydroergosterol (DHE) is a natural sterol with intrinsic fluorescence properties, which is found in low amounts in *S. cerevisiae*^{22,23}. DHE is very similar to ergosterol in structural and chemical properties with only single double bond difference and it can replace ergosterol in yeast without any functional interference²⁴. To test whether Upc2 directly binds to yeast sterols, we performed the fluorescent DHE-binding assay using purified CTDs of recombinant Upc2 (residues 598–913).

Figure 1 | Specific binding of Upc2 LBD to ergosterol and DHE. (a) Schematic presentation of the domain structures of Upc2 and Ecm22 in *S. cerevisiae* (*S.c.*) and *C. albicans* (*C.a.*). (b) Binding curves of DHE for wild-type Upc2 LBD and the C-terminal truncation mutant of Upc2 LBD ($\Delta 878$ –913). Intensities of fluorescence emission at the 375 nm of the samples ($\lambda_{\text{ex}} = 285$ nm) were plotted with increasing amounts of DHE concentrations. Each data point shown is the average of three measurements with error bars representing the s.d. Fit curves to data points were calculated based on one-site-binding model. One set of fluorescence emission spectra for wild-type Upc2 LBD was shown in the right panel. Five tryptophan residues that are located within 15 Å from the binding pocket were indicated by red spheres on the right panel. (c) Real-time measurement of DHE extraction by Upc2 LBD from large DOPC liposomes. The liposomes contained total 124 μM of phosphatidylcholine and DHE in a 98:2 molar ratio. Upc2 LBD was added to the liposomes with the final concentration of 0.73 μM at the beginning of kinetic measurement. Non-fluorescent ergosterol or cholesterol was added to the final concentration of 2.5 μM at 40 min for competitive binding to DHE. (d) Fluorescence emission spectra ($\lambda_{\text{ex}} = 285$ nm) of the samples during and at the end of the kinetics are shown for c. (e) Fluorescence emission spectra ($\lambda_{\text{ex}} = 285$ nm) of various sterols for competitive binding to DHE. The 0.6 μM of Upc2 LBD was loaded with 2.5 μM of free DHE. Three different lines in each experiment represent different concentrations of competing ligands (25-hydroxycholesterol, 20-hydroxycholesterol, hydrocortisone and β -estradiol) with 2.5, 4 and 10 μM respectively. β -estradiol is a naturally fluorescent compound. Asterisk indicates the intrinsic fluorescence emission of β -estradiol at 310 nm ($\lambda_{\text{ex}} = 285$ nm). (f) Fluorescence emission spectra of Ecm22 LBD on DHE binding.

Tryptophan residues of Upc2 were excited at 285 nm and the fluorescence spectrum of DHE was monitored. Spectral analysis revealed that tryptophan quenching at 340 nm was concomitant with the appearance of three emission peaks at 354, 373 and 393 nm (Fig. 1b). These peaks are characteristic of DHE, which suggests fluorescence resonance energy transfer (FRET) from Upc2 LBD to bound DHE^{25,26}. Upc2 LBD binds free DHE with nanomolar affinity as measured by equilibrium-binding experiments (Fig. 1b). Upc2 LBD also extracts and binds DHE embedded in the DOPC (1,2-dioleoyl-*sn*-glycero-3-phosphocholine) liposomes as monitored by the increase of fluorescence emission at 375 nm when Upc2 LBD was added to DOPC:DHE liposomes (Fig. 1c,d). When non-fluorescent ergosterol was added to the mixture containing DHE-bound Upc2, the fluorescence emission was decreased indicating that ergosterol competes with DHE for the binding to Upc2. However, the addition of cholesterol did not affect the DHE binding indicating that Upc2 does not bind cholesterol. Other sterols such as 20-hydroxycholesterol, 25-hydroxycholesterol, hydrocortisone and β -estradiol did not compete with DHE suggesting that Upc2 LBD is a specific receptor for fungal sterols such as ergosterol and DHE (Fig. 1e). In addition, to examine the DHE and ergosterol extraction properties of Upc2 from the liposomes with a physiological lipid composition of yeast plasma membranes²⁷, we monitored the extraction of DHE from the liposomes with phosphatidylcholine/phosphatidylethanolamine/phosphatidylinositol/phosphatidylserine/DHE (40:40:10:8:2, mol %) and the competitive binding of ergosterol with subsequent addition of the liposomes with phosphatidylcholine/phosphatidylethanolamine/phosphatidylinositol/phosphatidylserine/ergosterol (25:25:10:10:30, mol %) at 6.5 μ M and 23 nM of liposomes and protein, respectively (Supplementary Fig. 1). Upc2 binds DHE and ergosterol in a similar manner to that of DOPC/DHE liposomes. Ecm22, the close homologue of Upc2, also binds to free DHE in the same manner as that of Upc2 (Fig. 1f).

To compare the sterol ligands identified by *in vitro* experiments with the natural ligand captured by Upc2 from yeast cell

lysate, we characterized the ligand extracted by Upc2 using reversed-phase high-performance liquid chromatography (HPLC) and liquid chromatography-mass spectroscopy analyses (Fig. 2). The captured ligand was exclusively ergosterol with no detectable species of other lipids. Given the similarities in structural and chemical properties between ergosterol and DHE, and that ergosterol is far more abundant than DHE in yeast cells, we concluded that ergosterol is a physiological ligand for Upc2.

Upc2 LBD displays a novel α -helical fold. To examine the structure of the C-terminal LBD of Upc2, we performed the crystallographic studies on various C-terminal constructs. The crystals of apo Upc2 LBD and ergosterol-bound Upc2 LBD were crystallized but they did not diffract at synchrotron radiation. To improve the diffraction quality of Upc2 LBD crystals, we engineered a fusion protein (Upc2 LBD-T4L) in which T4 lysozyme replaces the variable loop (residues 715–725) in Upc2 (ref. 28). Upc2-T4L fusion protein was expressed stably and displayed good DHE-binding properties (Fig. 3a), which suggests that the T4 lysozyme fusion does not interfere with the ligand binding and the protein folding. The structure of the C-terminal LBD of apo Upc2 (residues 598–878)-T4L lacking the C-terminal 35 residues was determined to 2.9 Å resolution by the single anomalous dispersion method using selenomethionine-labelled crystals. The final structure containing two molecules of Upc2-T4L and 29 water molecules in the asymmetric unit was refined to an *R*-factor of 24.9% (Table 1).

The structure of apo Upc2 LBD displays a globular α -helical fold with an oval shape (Fig. 3b). The Upc2 LBD is composed of 11 α -helices and connecting loops. There is a small predicted α -helix (α 12, residues 889–896) in the C-terminal loop region that was not included in the crystallized construct. The 11 α -helices are arranged to form a closed clamp that creates a deep pocket in the core of the protein. The first three α -helices compose the N-terminal fingers and the helices α 8– α 9, α 7 and

Figure 2 | HPLC and liquid chromatography-mass spectroscopy analyses of the ligand captured by Upc2 from yeast cell lysate. (a) Reversed-phase HPLC elution profile of pure ergosterol standard (Sigma 45480) and the ligand extracted from Upc2 LBD. (b) Mass spectroscopy analysis of ergosterol standard and the ligand extracted from Upc2 LBD. Identification of the ligand captured by Upc2 was achieved by comparison of chromatographic properties and mass spectroscopy with the reference standard and literature data⁵⁶. AMU, atomic mass unit; UV, ultraviolet.

Figure 3 | Structure of Upc2 LBD. (a) Fluorescence emission spectra of Upc2 LBD-T4L fusion construct (residues 598-913) on DHE binding. (b) Overall structure of Upc2 LBD. The structure was coloured with red to blue based on the secondary structure succession. The T4 lysozyme fused in the $\alpha 5$ - $\alpha 6$ loop was not shown for clarity. (c) Overall structure of Upc2 LBD-T4L dimer with cylindrical representation. The location of deep hydrophobic pocket in one of the Upc2 protomers is indicated by a black circle. (d) Surface representation of Upc2 LBD monomer. The residues composing the wall of the hydrophobic pocket are shown in sticks. The hydrophobic pocket is shown in grey surface representation. Conc., concentration; C-term, C-terminal; N-term, N-terminal.

$\alpha 11$ compose the other fingers of the clamp. The four helices $\alpha 3$ - $\alpha 6$ compose the central palm as a helical bundle. The $\alpha 7$ - $\alpha 8$ loop (residues 760-799) surround the helices $\alpha 8$ - $\alpha 9$ as a longest random coil in the structure. The T4 lysozyme replacing nine residues in the $\alpha 5$ - $\alpha 6$ loop is closely located on the surface of Upc2 LBD (Fig. 3c).

The structure of Upc2 LBD reveals a central hydrophobic pocket surrounded by α helices (Fig. 3d). The deep hydrophobic pocket has a volume of $287 \text{ \AA}^3$. The helices $\alpha 5$ and $\alpha 6$ compose the bottom of the pocket and the helices $\alpha 1$ - $\alpha 2$, $\alpha 7$, $\alpha 9$ and $\alpha 11$ compose the wall of the hydrophobic binding pocket. The pocket is accessible to a solvent with a small pore on the surface. The presence of a hydrophobic pocket suggested to us that it may serve as a binding site for small lipophilic molecules. Structural comparison of Upc2 with known structures in the PDB using the DALI server did not find related structures with Z scores > 7 suggesting that the Upc2 LBD represents a novel fold of a LBD.

Upc2 LBD forms a constitutive homodimer. Size-exclusion chromatography (SEC) analysis demonstrated that the recombinant Upc2 LBD or Upc2 LBD-T4L is a homogeneous dimer without a detectable monomeric species, suggesting that dimeric Upc2 is a biologically relevant form. The dimer of Upc2 LBD contains two sterol-binding sites and the ligand binding did not affect the oligomeric state of Upc2 as analysed by SEC (Fig. 4a). There were two molecules of Upc2 LBD-T4L related by a non-crystallographic two-fold axis in the asymmetric unit of the crystals. Upc2 LBD dimerizes by helices $\alpha 1$ and $\alpha 2$ forming a four-helix bundle in the dimer interface (Fig. 4b). The N termini of Upc2 LBD dimer are exposed to the same side near the center of dimer interface. The dimer interface is mainly composed of

hydrophobic residues burying $1,562 \text{ \AA}^2$ of surface area at the interface (Fig. 4c). The Met610 is located in the center of dimer interface. M610R mutant is a monomer in solution analysed by SEC suggesting that the dimer observed in the crystal structure is consistent with that observed in solution (Fig. 4a). The LBDs of *C. albicans* Upc2 and *S. cerevisiae* Ecm22 are also dimers in solution and the M506R mutation of *C. albicans* Upc2 led to the monomerization of the LBD. The conservation of the residues composing the dimer interface in Upc2 homologues suggests that the homodimerization of LBDs is a general feature of these proteins (Supplementary Fig. 2).

The C-terminal loop is essential for ligand binding. The majority of the constitutive activation mutations in *S. cerevisiae* Upc2 and *C. albicans* Upc2 are clustered in the C-terminal loop between helix $\alpha 11$ and the predicted $\alpha 12$ helix^{21,29}. The crystal structure does not include this C-terminal activation loop of 35 residues. To examine the functional importance of this C-terminal loop, we performed the ligand-binding assays on the C-terminal deletion mutants of Upc2 LBD (Fig. 5a). Truncation of the C-terminal 14 residues ($\Delta 900$ -913) did not affect ligand binding. However, deletion of the C-terminal 35 residues ($\Delta 879$ -913), including the predicted $\alpha 12$, abolished DHE binding, suggesting that the C-terminal glycine rich loop and helix $\alpha 12$ are essential for ligand binding (Fig. 5b). In addition, G888D, a constitutive activation mutation in the $\alpha 11$ - $\alpha 12$ loop inhibited DHE binding significantly.

The crystal structure of Upc2 LBD shows a deep hydrophobic pocket that might accommodate a single sterol molecule. However, the size of the binding pocket in apo Upc2 LBD lacking the C-terminal activation loop is slightly smaller than the

Table 1 | Data collection and refinement statistics.

Crystal	Se-Met apo Upc2
Data collection	
Space group	$P3_2$
Cell dimensions	
a, b, c (Å)	67.17, 67.17, 257.51
α, β, γ (°)	90, 90, 120
Wavelength (Å)	0.97921 (peak)
Resolution (Å)	50–2.9 (3.06–2.90)
R_{merge} (%)	9.4 (35.8)
$I/\sigma I$	12.8 (3.7)
R_{pim}	0.041 (0.160)
R_{meas}	0.117 (0.422)
Completeness (%)	99.8 (99.0)
Redundancy	7.8 (6.7)
Wilson B -factor	80.2
Refinement	
Resolution (Å)	50–2.9 (3.08–2.90)
No. of reflections	28,729 (4712)
$R_{\text{work}}/R_{\text{free}}$	0.249 (0.388)/0.271 (0.422)
No. of atoms	6,828
Protein	6,799
Water	29
Average B -factors (Å ²)	65.97
Protein	66.07
Water	43.22
r.m.s. deviations	
Bond lengths (Å)	0.005
Bond angles (°)	1.3

r.m.s., root mean square.

A single crystal was used for data collection.

Highest-resolution shell is shown in parenthesis.

dimensions of ergosterol implying that Upc2 LBD must undergo a conformational change on ligand binding. To identify the structural determinants for sterol binding of Upc2, we tried to co-crystallize Upc2 LBD with ergosterol. However, due to the poor diffraction of sterol-bound Upc2 crystals, the structural determination of the ligand complex was not possible. Alternatively, we tested the effect of several mutations in the hydrophobic pocket on sterol binding. The mutation of residues distal to the pocket, V699Y and R752A, did not affect ligand binding. Mutation of residues in the hydrophobic binding pocket to bulky residues (L703F and L820W) significantly reduced DHE binding confirming that the hydrophobic pocket accommodates sterol (Fig. 5b). In addition, the M610R mutation completely abolished the sterol binding, implying that the dimerization of Upc2 LBD is required for sterol binding. The LBDs of all Upc2 homologues in fungal species display a high degree of sequence conservation (Supplementary Fig. 2). Specifically, the residues located in the dimerization interface, ligand-binding pocket and the C-terminal activation loop are strictly conserved.

Cytosolic Upc2 relocates into the nucleus on activation. The unique structural and ligand-binding features of Upc2 suggested to us that Upc2 may relocate to nucleus on ligand binding in the cytosol. We examined the cellular localization of full-length Upc2 and its mutants under ergosterol-rich or ergosterol-deficient conditions. Previously, there were several conflicting reports on the localization of Upc2 in the nucleus, cytoplasm and perinuclear foci using the C-terminal green fluorescent protein (GFP) fusion^{30–32}. However, the key determinants of Upc2 localization have not been experimentally defined. In this study, to avoid the functional interference of GFP with the C-terminal activation loop and ligand binding, GFP was tagged to the N terminus of

Upc2. Wild-type Upc2 is present mostly in the cytosol with mild nuclear localization in 30% of the cell population. When the yeast cells were grown in the presence of 5 mM ergosterol, Upc2 was localized almost exclusively to the cytoplasm. However, addition of 4 $\mu\text{g ml}^{-1}$ of fluconazole to the culture media, which inhibits the biosynthesis of ergosterol, shifted the localization of Upc2 to nucleus in an entire cell population (Fig. 6). Upc2 contains a bipartite nuclear localization signal (NLS) upstream of its Zn₂-Cys₆ cluster sequence that confers an intrinsic nuclear localization property. The deletion of NLS (residues 2–43) made Upc2 completely cytosolic. In addition, the isolated LBD (residues 598–913) or the construct lacking NLS-DBD (construct residues 283–913) was completely cytosolic regardless of sterol levels. In contrast, deletion of the C-terminal LBD (Δ LBD, construct residues 1–559) showed strong nuclear localization independent of sterol levels. These data suggest that the ergosterol-bound C-terminal LBD suppresses the nuclear transport of Upc2 by inhibiting the NLS function. The dissociation of sterol ligand from Upc2 may lead to exposure of the NLS or release Upc2 from the capture by cytosolic proteins for nuclear transport. The deletion of the C-terminal loop (Δ 879–913) that disrupts ergosterol binding led to modest nuclear localization of Upc2. G888D or mutations in the sterol-binding pocket (L820W or L703F) led to strong constitutive nuclear localization of Upc2. The M610R mutation that disrupts dimerization of LBD and ligand binding shows mostly nuclear localization regardless of sterol level, suggesting that dimerization of Upc2 is essential for its regulatory function. In conclusion, these observations together with ligand-binding assays suggest that sterol binding is the key mechanism in regulating the localization of the TF. In a sterol-rich condition, Upc2 is bound to ergosterol and is present in the cytosol as a repressed form. On depletion of ergosterol, unliganded Upc2 is activated and moves to the nucleus for transcriptional activation of related genes.

Upc2 regulates ergosterol level in yeast cells. Upc2 and Ecm22 bind to a conserved 7-bp sterol regulatory element within promoters of most *ERG* genes including *ERG2*, *ERG3* and *ERG11* (refs 2,21). To investigate the mechanism of transcriptional regulation of Upc2, we check the transcriptional activity of various Upc2 constructs using *ERG2-LacZ* as a reporter (Fig. 7a). The wild-type Upc2 displayed a moderate transcriptional activity in a normal growth condition. Fluconazole treatment increases the transcription activity more than two times. However, empty plasmid or deletion of the C-terminal LBD showed very weak transcription activity suggesting that LBD is essential for the transcriptional activity of Upc2. G888D mutation, regardless of fluconazole treatment, showed a full constitutive activation of Upc2, which is 1.2 times higher than the induced wild type. This observation is consistent with the previous report that the CTD is essential for the transcription activation of Upc2 (ref. 21). The M610R showed no increase of transcriptional activity on sterol depletion suggesting that dimerization is essential for the regulatory function. Deletion of the C-terminal activation loop (Δ CT) that shows constitutive nuclear localization, however, displayed at least 30% lower transcriptional activity than uninduced wild type. In addition, the transcription activity of Δ CT did not increase on fluconazole treatment. These data suggest that the C-terminal activation loop is essential not only for the regulation of protein localization but for the full transcription activity of Upc2. Disruption of sterol binding by L703F or L820W showed constitutive nuclear localization. However, the transcription activities of these mutants were 40% less than the wild type and were not enhanced significantly on fluconazole induction. It seems that introduction of bulky

Figure 4 | Upc2 LBD forms a dimer. (a) Profiles of SEC for LBDs of *S. cerevisiae* (S.c.) Upc2, *C. albicans* (C.a.) Upc2 and *S. cerevisiae* Ecm22. Profiles of wild type and the dimer interface mutants (M610R in *S. cerevisiae* Upc2 and L506R in *C. albicans* Upc2) are shown in blue and green, respectively. The profiles of ergosterol-bound Upc2 and Ecm22 LBDs are shown in red lines. Ergosterol-bound LBDs were prepared by mixing purified LBDs and ergosterol in a 1:5 molar ratio and the mixture was incubated overnight before SEC analysis. (b) Side view of the Upc2 LBD dimer. (c) Detailed view of the Upc2 dimer interface. One protomer is shown in rainbow color and the other in white.

Figure 5 | Sterol-binding pocket of Upc2. (a) Fluorescence emission spectra of various mutants on DHE binding. The emission spectra at several time points were shown in different colours. (b) Ribbon representation of the hydrophobic pocket. The hydrophobic pocket is shown in grey surface representation. The speculative trace of the C-terminal activation loop that was not included in the crystallized construct is shown in red dots.

Figure 6 | Cellular localization of GFP-Upc2 constructs. Cells were grown in $4 \mu\text{g ml}^{-1}$ of fluconazole or 5 mM of ergosterol for 12 h before visualization by fluorescence microscopy. Top panels show the localization of GFP-Upc2. DAPI stains both nuclear DNA as spheres and mitochondrial DNA as bright speckles which obscure features of nuclear DNA segregation. Nuclear DNA can be distinguished from mitochondrial DNA by its size and shape. Nuclear localization of Upc2 appears as bright green spheres inside the cells. Scale bar, 3 μm .

residues to the sterol-binding pocket not only disrupt sterol binding but also perturb the proper conformation of Upc2 for full transcriptional activity. These observations together with ligand binding and cell localization experiments suggest that sterol binding not only regulates protein localization but also regulates transcriptional activity of Upc2. To confirm that Upc2 is involved in the regulation of ergosterol level in the cells, we quantified total ergosterol contents of yeast cells containing wild-type or mutant *UPC2* alleles (Fig. 7b). Since Upc2 activates the expression of ergosterol biosynthetic genes, it is conceivable that the sterol level of the yeast cells indirectly correlates with the transcriptional activity of Upc2. In the absence of *UPC2* and *ECM22* genes, sterol levels of yeast cells were weakly detectable, and the addition of $4 \mu\text{g ml}^{-1}$ fluconazole severely inhibited yeast cell growth. Wild-type Upc2 displayed a similar ergosterol level in the cell

with those of L703F and L820W in the absence of fluconazole. The fluconazole treatment suppressed the ergosterol level by around 40% in wild type, L793F and L820W strains. Deletion of the C-terminal 35 residues (ΔCT) resulted in a slightly higher level of ergosterol than wild-type cells. However, fluconazole suppressed the sterol level of ΔCT and M610R mutant cells than wild-type cells more significantly. Upc2 lacking LBD showed some basal level of sterol synthesis in the absence of fluconazole. However, the presence of $4 \mu\text{g ml}^{-1}$ fluconazole inhibited the sterol level and cell growth significantly. The cells expressing G888D mutant have three times higher ergosterol levels compared with the cells expressing wild-type Upc2. Ergosterol levels were higher in fluconazole-treated G888D mutant cells compared with those found in wild-type cells grown without fluconazole. These data suggest that the G888D mutation constitutively

Figure 7 | Ergosterol level and antibiotic resistance. (a) Transcriptional activity of Upc2. *ERG2-lacZ* reporters were used to determine the contribution of each Upc2 constructs to the regulation of *ERG2* promoter. β -Galactosidase assays were performed on each transformants after 5 ml cultures were grown for 16 h either in minimal medium (uninduced) or in the minimal medium containing 4 $\mu\text{g ml}^{-1}$ of fluconazole (induced). The assay values represent the average of three independent experiments. All error bars indicate s.d. *P* values were assessed by two-tailed Student's *t*-test. **P* < 0.05 versus wild type, #*P* < 0.05 versus each mutant without fluconazole. (b) Quantification of total ergosterol in yeast cells. Yeast *upc2Δ ecm22Δ* strains containing various *UPC2* alleles were analysed for their ergosterol contents. Each data point is the average of three measurements. All error bars indicate s.d. *P* values were assessed by two-tailed Student's *t*-test. **P* < 0.05 versus wild type, #*P* < 0.05 versus fluconazole-treated wild-type. (c) Susceptibilities to fluconazole of yeast strains expressing wild-type or mutant *UPC2* allele. The strains were initially grown without fluconazole and the dilution series were spotted on the agar plates containing fluconazole and incubated for 36 h.

activates Upc2 for the biosynthesis of ergosterol, which leads to an increased resistance to azole antifungals. To confirm that Upc2 is involved in the regulation of gene expression of ergosterol biosynthetic enzymes, we performed quantitative gene expression analysis of *ERG11* by real-time PCR using the *upc2/ecm22*-knockout strains with wild-type and mutant *UPC2* alleles. We measured the mRNA levels of *ERG11* genes that were normalized by *TAF10* gene as an internal control³³. The data indicate that the mRNA expression levels of *ERG11* correlate with the promoter activities of *ERG2* and ergosterol levels as expected (Supplementary Fig. 3).

Activation of Upc2 confers resistance to antifungal agent. To investigate the relationship between the activation of Upc2 and

the resistance to antifungal agents, we checked the fluconazole susceptibilities of *upc2Δ ecm22Δ* or *ecm22Δ* strains expressing wild-type or mutant *UPC2* alleles (Fig. 7c). Since fluconazole interferes with yeast cell growth by inhibiting ergosterol biosynthesis, the overall patterns of cell growths displayed a correlation with the sterol levels of the cells treated with fluconazole. Double knockout cells of *upc2Δ ecm22Δ* did not grow in the presence of fluconazole. Introduction of wild-type *UPC2* permitted weak cell growth at 8 $\mu\text{g ml}^{-1}$ of fluconazole. The yeast cells expressing a G888D mutant showed a significant increase of resistance to fluconazole at 8 $\mu\text{g ml}^{-1}$. However, G888D mutant grew more weakly than wild type in the absence of fluconazole suggesting that full constitutive activation of Upc2 is disadvantageous under non-selective condition by imposing metabolic burden³⁴. ΔLBD mutant lacking transcription activity did

not grow at the lowest fluconazole concentration. L820W, L703F, M610R and Δ CT mutants that interfere with sterol binding were more susceptible to fluconazole than the wild type. Single *upc2 Δ* -knockout strain harbouring *ECM22* allele permitted weak growth in a low concentration of fluconazole suggesting that *ECM22* has a partially overlapping role in activating genes involved in azole resistance. However, in the fluconazole concentrations higher than $6 \mu\text{g ml}^{-1}$, *upc2 Δ* and *upc2 Δ ecm22 Δ* strains did not display significant differences in the susceptibilities of all Upc2 constructs, suggesting that Upc2 plays a dominant role in the sterol regulation. This is consistent with the previous observations that deletion of *UPC2* results in ketoconazole sensitivity, whereas no effect was observed with *ECM22* deletion suggesting that Ecm22 and Upc2 have specific targets with some essential overlapping functions^{35,36}.

Upc2 is a novel class of zinc finger TFs. Recent studies proposed that several members of the fungal zinc cluster family of transcription regulators may represent functional analogues of metazoan NRs^{13,18–20}.

While fungal zinc cluster TFs have no apparent sequence or structural similarity to metazoan NRs, Upc2 displays conceptual similarities with steroid NRs in general domain architectures, sterol ligand binding, homodimerization, ligand-dependent transcriptional regulation and nuclear translocation.

Upc2 and metazoan NRs both contain zinc finger DNA-binding domains in their N-terminal regions. Zinc fingers coordinating two zinc ions are composed of six cysteines for Upc2 and four cysteines in each of the two fingers for NRs³⁷. The DNA-binding domains of NRs and zinc cluster TFs are structurally similar and they bind to DNA as homo- or heterodimers¹³. Zinc finger TFs have a C-terminal negative regulatory domain, which for a number of family members mediates ligand binding or response to small molecules such as cellular metabolites and lipophilic ligands¹³. Transcriptional activity of Upc2 is regulated by ergosterol, which is functionally similar to Type I steroid NRs in terms of ligand specificities. Upc2 and steroid receptors both form homodimers. Upc2 forms constitutive homodimers regardless of ligand binding. Oestrogen receptor α has been reported to exist as a dimer even in the apo state and the ligand binding further stabilize the homodimer³⁸.

Figure 8 | Schematic model of transcriptional regulation by Upc2.

In a sterol-rich condition, Upc2 binds to ergosterol and stays in the cytosol as a repressed form perhaps by hiding NLS or by being captured with a cytosolic protein. On ergosterol depletion, ligand-free Upc2 undergoes conformational activation and moves to nucleus for transcriptional activation of related genes.

Structural comparison of Upc2 with mammalian steroid NRs reveals that Upc2 has a distinctive α -helical fold of LBD from mammalian NRs (Supplementary Fig. 4). Both gene regulators are mainly composed of around 12 α -helical structures with similar dimensions of LBDs. LBDs of Upc2, oestrogen and progesterone receptors form dimers by helix bundle interactions. However, except the overall configuration of dimers with ligand-binding sites closely located to the dimer interface, there is no clear structural homology between Upc2 and the NRs. On ligand binding, steroid receptors dissociate from heat shock protein Hsp90 in the cytosol and translocate to the nucleus, binding to their target gene promoters as homodimers¹⁷. Consistently, the translocation of Upc2 from the cytosol to the nucleus is regulated in a ligand-dependent manner.

However, Upc2 LBD displays a completely different structural fold compared with the LBDs of metazoan NRs. The lack of sequence and structural similarities of fungal zinc cluster TFs and metazoan NRs suggests that the architectural and functional similarities are the product of convergent evolution with common mechanistic strategy. Phylogenetic analysis shows that the orthologues of Upc2 are only identifiable within the Saccharomycotina and Upc2/Ecm22 proteins form monophyletic clade that is not closely related to any other $\text{Zn}_2\text{-Cys}_6$ proteins of Saccharomycotina⁵. The budding yeast, *S. cerevisiae*, contains around 50 $\text{Zn}_2\text{-Cys}_6$ TFs³⁹. Even though sequence homology of Upc2 to other types of zinc finger TFs is low, they harbour a conserved fungal-specific sequence within the C-terminal LBDs that was previously known as the MHR (middle homology region)⁴⁰. The C-terminal region, including the MHR, in zinc TFs commonly contains 13–15 α -helices of secondary structure elements, which implies that the presence of a LBD is a general feature of this protein family. In conclusion, Upc2 represent a novel class of zinc finger TFs displaying a functional analogy with metazoan steroid receptors.

Discussion

The crystal structure of Upc2 LBD together with biochemical and yeast cell biology studies provides a detailed mechanistic picture of transcriptional regulation (Fig. 8). Upc2 specifically recognizes ergosterol, which is the final product of the sterol biosynthetic pathway in fungi. Apo Upc2 localizes in the cytosol and is able to extract sterols from the lipid membranes. Since the majority of ergosterol in the cell is distributed in the plasma membranes, sensing the sterol level in the cytosol correlates well with its regulatory function. Dissociation of ergosterol leads to the relocalization of Upc2 from cytosol to nucleus. The N-terminal DNA-binding domain with NLS has an intrinsic capability of nuclear localization and the C-terminal LBD, when bound to ergosterol, masks its nuclear localization capability. Ligand-bound Upc2 might be captured by cytosolic proteins or hide the N-terminal NLS sequence from recognition by nuclear transport proteins such as importins^{41,42}. The molecular chaperone Hsp90 mediates haem activation of the yeast zinc TF Hap1 by direct physical interactions⁴³, which is similar to the mechanism of steroid NR-Hsp90 complexes in the regulation of ligand-binding, translocation and transcription⁴⁴. The genetic interaction of Hsp90 and Upc2 in *C. albicans* was previously reported⁴⁵. In addition, the Hsp90-mediated morphogenesis of *C. albicans* occurs via Upc2 (ref. 46). These studies raise interesting questions regarding the relationship of Upc2 and Hsp90 that requires further investigation. Ligand binding generally leads to transcriptional activation in many fungal $\text{Zn}_2\text{-Cys}_6$ TFs¹³. Upc2 displays an inverse regulatory mechanism in which ligand binding represses the transcriptional activity of Upc2. In Upc2, the C-terminal 30 residues are

defined as an ‘activation loop’. It contains a highly conserved glycine residues connected to the predicted two-turn amphipathic α -helix (α 12). The activation loop in Upc2 is not only involved in sterol binding and regulation of protein localization, but also involved in transcriptional activation. The conformational flexibility of the C-terminal activation loop seems to be essential for the ligand binding and for the transcriptional regulation. Any substitution larger than alanine at G888 results in an increase of gene expression similar to that of the original G888D mutation²¹. Upc2 Δ CT does not bind DHE and it shows constitutive nuclear localization. G888D mutation in the activation loop also abolishes DHE binding, which indicate subtle changes in the activation loop have a significant influence on ligand binding properties. This suggests that the activated form of apo Upc2 LBD has a different conformation from the ligand-bound state. The structure of Upc2 LBD Δ CT shows a deep hydrophobic pocket (287 Å³) that has a volume smaller than the value of ergosterol (427 Å³). We suppose that the Δ CT or G888D mutations lead to an irreversible change to the activated conformation of LBD. Dissociation of ergosterol from the Upc2 LBD might result in conformational changes that liberate the C-terminal activation loop from intramolecular inhibitory contacts, allowing recruitment of transcriptional coactivators. In yeast, the mediator Galp/MED15 is known to play a critical role as a subunit of coactivators for Oaf1 and Pdr1 TFs^{18,20}. Currently, the downstream coactivator of Upc2 is unknown. Discovery of the coactivator for Upc2 and the mechanistic characterization of coactivator regulation would provide important clues for the relationship between fungal zinc cluster TFs and metazoan NRs.

Many zinc cluster TFs bind small-molecule intermediates, substrates or end products of the metabolic pathways that are under their transcriptional controls¹³. In contrast, many mammalian NRs bind small molecules of extracellular origin. Therefore, fungal zinc cluster TFs seem to have evolved to monitor and regulate the metabolic pathways by sensing their key compounds. Some fungal species that contains SREBP homologues do not harbour the *UPC2* gene and vice versa, implying that they might have developed separate regulatory mechanism of sterol homeostasis during evolution⁵. Depletion of sterol levels by azole antifungals stimulates the activation of sterol uptake genes by Upc2 (ref. 2). Although there are several structural differences between cholesterol and ergosterol, they both efficiently support the growth of *S. cerevisiae* and *C. glabrata* incapable of ergosterol biosynthesis⁴⁷. Since the human body under azole treatment provides conditions favouring the stimulation of sterol import from the fungal environment, the ability of *C. glabrata* to replace ergosterol with a host sterol may be responsible for its elevated azole resistance *in vivo*^{6,47}. The deletion of *UPC2* leads to anaerobic inviability and high susceptibility to azole antifungals in *S. cerevisiae* and in *C. albicans*^{6,14}. Therefore, the inhibition of Upc2, which subsequently suppresses the adaptive responses of fungal cells to azoles, could be a novel strategy to improve the combined therapy with antifungal agents^{16,48}.

In this study, we uncovered the mechanism of how Upc2 senses sterol levels and activates the ergosterol biosynthetic pathway. Upc2 LBD displays a novel fold of LBD and a deep hydrophobic pocket that could serve as an excellent pharmacophore for the design of small-molecule inhibitors. In addition, Upc2 is specific to fungal sterols and has no affinities to other types of sterols providing key information for ligand-based drug design. Thus, the discovery of Upc2 as a novel class of ligand-dependent TFs opens the way for the development of new antimicrobial agents.

Methods

Preparation of recombinant proteins. Details of construct design, protein expression and crystallographic procedures were described elsewhere²⁸. In brief, DNA encoding various portions of Upc2 (UniProt id: Q12151) was amplified by PCR using *S. cerevisiae* genomic DNA as a template. The PCR products were subcloned into the NdeI and XhoI sites of a pET28b vector. The variable region (residue 715–725) in Upc2 was replaced by a dipeptide sequence (Val-Asp) of the SalI restriction enzyme recognition sequence by PCR-based mutagenesis. To improve the diffraction quality of Upc2, a DNA encoding T4 lysozyme (residues 2–161) with SalI restriction enzyme sites in 5′ and 3′ overhangs was inserted into the SalI site of pET28b-UPC2. The pET28b-UPC2-T4L (residues 598–878, 715–725 Δ :T4L) was transferred into an *Escherichia coli* strain BL21(DE3) cells and the protein was expressed by addition of 0.5 mM isopropyl β -D-1-thiogalactopyranoside. Cells expressing His-Upc2-T4L were resuspended in 2 $\times$ PBS, 20 mM imidazole and were lysed by sonication. The supernatant containing His-Upc2-T4L was applied to a Ni-NTA affinity column. The eluted sample in 0.1 M Tris-HCl pH 7.5, 0.3 M imidazole, 0.3 M NaCl was concentrated to 10 mg ml^{−1} and the His-tag was removed by cleavage with thrombin protease. Upc2-T4L was subjected to SEC on a Superdex 200 column (GE Healthcare) equilibrated with 20 mM Tris-HCl pH 8.0, 0.3 M NaCl. The peak fractions containing Upc2-T4L were concentrated to 10 mg ml^{−1} for crystallization. Purification of selenomethionyl Upc2-T4L constructs essentially followed the same procedure using a methionine pathway inhibition technique using a heterotrophic *E. coli* strain⁴⁹. For the ligand-binding assay, various C-terminal constructs of Upc2 and their mutants were cloned into pET28b and the proteins expressed and purified using the procedure described above.

Crystallization and crystallographic analysis of Upc2-T4L. Upc2 LBD-T4L crystallized in space group P3₂ with two copies in the asymmetric unit and a solvent content of 0.64. Se-SAD data sets were collected to 2.9 Å resolution at the peak wavelength of 0.97921 Å at the Photon Factory AR-NW12A beamline. SAD phasing was carried out at 3.0 Å resolution using the programme SOLVE. Twenty-two Se sites out of a total of 24 selenomethionines in the Upc2-T4L dimer were found by automated heavy atom search with a figure of merit of 0.44. The phases were further improved by density modification using the programme RESOLVE⁵⁰. The resulting electron density maps with a figure of merit of 0.70 were readily interpretable. Two molecules of Upc2 and one molecule of T4L were clearly visible in the electron density maps. The N-terminal subdomain (residues 15–56) of the second T4L molecule in the asymmetric unit was poorly defined in the electron density maps due to the disorder in the lattice. The structure of Upc2-T4L was built manually using the programme Coot⁵¹. The structure of Upc2-T4L was refined to $R_{\text{work}}/R_{\text{free}}$ of 24.9%/27.1% using CNS⁵². The final model consisted of two copies of Upc2 (residues 604–878), two copies of T4 lysozyme (residues 2–161) and 29 water molecules. There are 95.4% of the residues in the most favoured and additional allowed regions of the Ramachandran plot. Seven residues have conformations in disallowed regions, and all of these are located in regions of high mobility at the extreme termini of chains or in the flexible loop regions. A stereo image of selected electron density is presented in Supplementary Fig. 5.

Liposomes. DOPC, DOPE (1,2-dioleoyl-*sn*-glycero-3-phosphoethanolamine), POPS (1-palmitoyl-2-oleoyl-*sn*-glycero-3-phospho-L-serine), were obtained from Avanti Polar Lipids Inc. Phosphatidylinositol (soybean), ergosterol and DHE were obtained from Sigma-Aldrich. The liposomes were prepared as described with slight modifications²⁶. Lipids in stock solutions in chloroform or in ethanol were mixed at the desired molar ratio, incubated at 37 °C for 5 min and the solvent was evaporated by nitrogen stream. The dried lipids were resuspended in 50 mM HEPES, pH7.2 and 120 mM potassium acetate (HK buffer) by vortexing. The liposomes were prepared at a total lipid concentration of 1.3 mM. The hydrated lipid mixture was frozen and thawed five times using water bath and cooled ethanol at −70 °C. The lipid mixture was extruded 10 times through a 0.1- μ m (pore size) polycarbonate filter. Liposomes were stored at 4 °C in the dark and used within 3 days.

Kinetic measurement of ligand binding using FRET. Fluorescent measurements of DHE binding to Upc2 LBD were based on FRET between Trp and bound DHE and were carried out using methods as previously reported^{26,53}. For kinetics measurements, Trp fluorescence was measured at 340 nm (bandwidth 5 nm) on excitation at 285 nm (bandwidth 5 nm) in a spectrofluorometer (FP-6200; JASCO). One ml of sample initially containing the liposomes (1.3 mM) was diluted two times with HK buffer. The liposomes were diluted with the buffer to desired concentrations right before the experiments. The sample (volume 2 ml) was placed in a square quartz cell and continuously stirred with a small magnetic bar at ambient temperature. Upc2 proteins were injected into the sample cell with a final protein concentration of 0.6 μ M and the kinetics measurement was started instantly. 2.5 μ M of free ergosterol or cholesterol was added to the mixture at 40 min and the measurement was continued for another 40 min. Emission spectra were recorded at several time points on excitation at 285 nm.

Free DHE-binding and competition assays. To measure the binding affinity of Upc2 to DHE, a serial dilution series of free DHE (0, 2.5, 5, 25, 50, 100, 250 and 500 nM) were mixed with 47 nM of Upc2 LBD and incubated for 14 h. On the basis of the amounts of protein and the ligand bound, free ligand concentrations in each point were calculated and used for one-site-binding model analysis. Emission at 375 nm was recorded with maximum sensitivity of fluorometer and the binding curve was fitted with a one-site-binding model using the programme SigmaPlot. To monitor the binding of other sterol ligands, a competition assay was performed. Upc2 LBD (0.6 μ M) was preloaded with DHE by incubating Upc2 and 2.5 μ M of free DHE for 6 h in ice. Increasing amounts of second sterol ligands (2.5, 5.0 and 10 μ M) were added and incubated for 2 h at room temperature before the emission spectra of the mixtures were recorded.

Reversed-phase HPLC and MS analyses. The purified His-tagged Upc2 LBD (5 mg) from *E. coli* in apo-form was incubated with yeast cell lysate (50 ml culture) for 30 min at room temperature. Upc2 LBD was isolated by Ni-NTA affinity chromatography. The sterol ligand captured by Upc2 was extracted to *n*-heptane as described⁵⁴. Three ml of 25% alcoholic potassium hydroxide solution was added to Upc2 LBD sample and vortex mixed for 1 min and the mixture was incubated at 85 °C for 1 h. Sterols were then extracted by addition of a mixture of 1 ml of distilled water and 3 ml of *n*-heptane followed by vortex mixing for 3 min. The heptane layer containing extracted sterol was collected for subsequent chromatographic analysis. Heptane was vacuum dried out and the sterol pellet was solubilized in methanol. The samples dissolved in methanol were analysed by RP-HPLC (Shimadzu 10Avp HPLC system) with a Thermo Hypersil BDS (C8) 50 $\times$ 3 mm, 3 μ m column and coupled with a triple-quadrupole equipped mass spectrometer (API2000, AB Sciex) with an ESI source. The mobile phase components were 0.05% trifluoroacetic acid in water and 0.05% trifluoroacetic acid in acetonitrile. We used a method based on an acetonitrile isocratic condition that allowed the detection of compounds. The products were eluted at a flow rate of 0.4 ml min⁻¹ with 75% acetonitrile, and monitored by determining absorbance at 280 nm. Compounds were identified based on their retention times and the masses detected in the liquid chromatography-mass spectrometry system were compared with the pure ergosterol standard (Sigma 45480).

Plasmid construction and yeast strains. The complete expression cassette and the open reading frame of Upc2 were amplified from yeast genomic DNA and cloned into YCplac33 and pRS413MET-GFP. Mutant constructs were generated by site-directed mutagenesis and confirmed by DNA sequencing. The *upc2Δ ecm22Δ* strain was prepared by replacing the *ECM22* gene with *LEU2* gene from an *upc2Δ* strain (BY4741, MATa *his3Δ1 leu2Δ0 met15Δ0 ura3Δ0*) by homologous recombination. Plasmids encoding the *UPC2* gene were transformed to the *upc2Δ ecm22Δ* strain (BY4741, MATa *his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 ecm22Δ::LEU2*).

Fluconazole susceptibility test. Fluconazole susceptibility testing was performed by introducing YCplac33 plasmids containing the full expression cassette of wild-type or mutant *UPC2* into the *upc2Δ ecm22Δ* strain. The transformed cells were grown at 30 °C until the cell density reached to OD₆₀₀ of 1. The serial dilutions of cells were spotted on agar plates containing fluconazole and incubated for 36 h.

Microscopy. Yeast strains expressing the appropriate *GFP-UPC2* alleles were grown to an OD₆₀₀ of 0.4–0.6 in selection media. Cells were grown with 4 μ g ml⁻¹ of fluconazole or 5 mM ergosterol. Yeast cells were labelled by adding DAPI (4',6-diamidino-2-phenylindole) at a final concentration of 5 μ g ml⁻¹ for mitochondrial and nuclear DNA staining. The cells were further incubated for 1 h before harvesting. The cells were washed two times with 1 $\times$ PBS and resuspended in selection media for observation under the microscope. Visualization of cells was performed on an Eclipse Ti fluorescence microscope (Nikon) equipped with fluorescein isothiocyanate and DAPI filters and the images were captured with an Andor ixon EMCCD camera.

Measurement of transcription activity. pRS413-*ERG2-lacZ* was an *ERG2-lacZ* reporter made by subcloning an *ERG2* promoter, *lacZ* DNA, into the multiple cloning sites of the pRS413MET vector. *ERG2* promoter from -751 to -1 was amplified by PCR from yeast genomic DNA. *lacZ* was amplified by PCR from *E. coli* genomic DNA. The 3' end of *ERG2* promoter was fused to the 5' end of *lacZ* open reading frame by PCR amplification. *ERG2-lacZ* DNA was subcloned to BamHI/XhoI sites of pRS413 vector. pRS413-*ERG2-lacZ* and the YCplac33-*UPC2* construct were co-transformed to the *upc2Δ ecm22Δ* strain. Five ml of yeast cells were grown to an OD₆₀₀ of 1 and the activity of β -galactosidase was measured as described⁵⁵.

Sterol quantification of yeast cells. Total intracellular sterols were extracted as described⁵⁴ with slight modifications. In brief, 5 ml overnight culture from a single *S. cerevisiae* colony was used to inoculate 50 ml of a selection medium containing 0, or 4 μ g ml⁻¹ of fluconazole. The cultures were incubated for 16 h at 30 °C. The stationary-phase cells were harvested by centrifugation at 2,700 r.p.m. for 5 min

and washed once with distilled water. Cell densities were measured based on OD₆₀₀ of the cultures and equal amounts of cells were processed for sterol extraction. Three ml of 25% alcoholic potassium hydroxide solution (25 g of KOH and 35 ml of sterile distilled water, brought to 100 ml with 100% ethanol) was added to each pellet and vortex mixed for 1 min. Cell suspensions were transferred to glass tubes and were incubated in an 85 °C water bath for 1 h. Following incubation, the tubes were allowed to cool to room temperature. Sterols were then extracted by addition of a mixture of 1 ml of distilled water and 3 ml of *n*-heptane followed by vortex mixing for 3 min. The heptane layer was transferred to a clean tube and stored at -20 °C. Before analysis, a 20- μ l aliquot of sterol extract was diluted fivefold in 100% ethanol and scanned spectrophotometrically between 240 and 300 nm with a NanoDrop 1000 Spectrophotometer (Thermo Fisher Scientific). The presence of ergosterol and DHE in the extracted sample resulted in a characteristic four-peak curve.

References

- Zhang, Y. Q. & Rao, R. Beyond ergosterol: linking pH to antifungal mechanisms. *Virulence* **1**, 551–554 (2010).
- Vik, A. & Rine, J. Upc2p and Ecm22p, dual regulators of sterol biosynthesis in *Saccharomyces cerevisiae*. *Mol. Cell. Biol.* **21**, 6395–6405 (2001).
- Porter, J. R., Burg, J. S., Espenshade, P. J. & Iglesias, P. A. Ergosterol regulates sterol regulatory element binding protein (SREBP) cleavage in fission yeast. *J. Biol. Chem.* **285**, 41051–41061 (2010).
- Hughes, A. L., Todd, B. L. & Espenshade, P. J. SREBP pathway responds to sterols and functions as an oxygen sensor in fission yeast. *Cell* **120**, 831–842 (2005).
- Maguire, S. L. *et al.* Zinc finger transcription factors displaced SREBP proteins as the major sterol regulators during *Saccharomycotina* evolution. *PLoS Genet.* **10**, e1004076 (2014).
- Zavrel, M., Hoot, S. J. & White, T. C. Comparison of sterol import under aerobic and anaerobic conditions in three fungal species, *Candida albicans*, *Candida glabrata*, and *Saccharomyces cerevisiae*. *Eukaryot. Cell* **12**, 725–738 (2013).
- Kwast, K. E. *et al.* Genomic analyses of anaerobically induced genes in *Saccharomyces cerevisiae*: functional roles of Rox1 and other factors in mediating the anoxic response. *J. Bacteriol.* **184**, 250–265 (2002).
- Dunkel, N. *et al.* A gain-of-function mutation in the transcription factor Upc2p causes upregulation of ergosterol biosynthesis genes and increased fluconazole resistance in a clinical *Candida albicans* isolate. *Eukaryot. Cell* **7**, 1180–1190 (2008).
- Hoot, S. J., Smith, A. R., Brown, R. P. & White, T. C. An A643V amino acid substitution in Upc2p contributes to azole resistance in well-characterized clinical isolates of *Candida albicans*. *Antimicrob. Agents Chemother.* **55**, 940–942 (2011).
- Heilmann, C. J., Schneider, S., Barker, K. S., Rogers, P. D. & Morschhauser, J. An A643T mutation in the transcription factor Upc2p causes constitutive ERG11 upregulation and increased fluconazole resistance in *Candida albicans*. *Antimicrob. Agents Chemother.* **54**, 353–359 (2010).
- Lewis, T. L., Keesler, G. A., Fenner, G. P. & Parks, L. W. Pleiotropic mutations in *Saccharomyces cerevisiae* affecting sterol uptake and metabolism. *Yeast* **4**, 93–106 (1988).
- Valachovic, M. *et al.* Cumulative mutations affecting sterol biosynthesis in the yeast *Saccharomyces cerevisiae* result in synthetic lethality that is suppressed by alterations in sphingolipid profiles. *Genetics* **173**, 1893–1908 (2006).
- Naar, A. M. & Thakur, J. K. Nuclear receptor-like transcription factors in fungi. *Genes Dev.* **23**, 419–432 (2009).
- MacPherson, S. *et al.* *Candida albicans* zinc cluster protein Upc2p confers resistance to antifungal drugs and is an activator of ergosterol biosynthetic genes. *Antimicrob. Agents Chemother.* **49**, 1745–1752 (2005).
- Whaley, S. G. *et al.* UPC2A is required for high-level azole antifungal resistance in *Candida glabrata*. *Antimicrob. Agents Chemother.* **58**, 4543–4554 (2014).
- Gallo-Ebert, C. *et al.* Novel antifungal drug discovery based on targeting pathways regulating the fungus-conserved Upc2 transcription factor. *Antimicrob. Agents Chemother.* **58**, 258–266 (2014).
- Gronemeyer, H., Gustafsson, J. A. & Laudet, V. Principles for modulation of the nuclear receptor superfamily. *Nat. Rev. Drug Discov.* **3**, 950–964 (2004).
- Thakur, J. K. *et al.* Mediator subunit Gal11p/MED15 is required for fatty acid-dependent gene activation by yeast transcription factor Oaf1p. *J. Biol. Chem.* **284**, 4422–4428 (2009).
- Phelps, C. *et al.* Fungi and animals may share a common ancestor to nuclear receptors. *Proc. Natl Acad. Sci. USA* **103**, 7077–7081 (2006).
- Thakur, J. K. *et al.* A nuclear receptor-like pathway regulating multidrug resistance in fungi. *Nature* **452**, 604–609 (2008).
- Davies, B. S., Wang, H. S. & Rine, J. Dual activators of the sterol biosynthetic pathway of *Saccharomyces cerevisiae*: similar activation/regulatory domains but different response mechanisms. *Mol. Cell. Biol.* **25**, 7375–7385 (2005).
- Schroeder, F. *et al.* Membrane cholesterol dynamics: cholesterol domains and kinetic pools. *Proc. Soc. Exp. Biol. Med.* **196**, 235–252 (1991).

23. Le Fur, Y., Maume, G., Feuillat, M. & Maume, B. F. Characterization by gas chromatography/mass spectrometry of sterols in *Saccharomyces cerevisiae* during autolysis. *J. Agric. Food Chem.* **47**, 2860–2864 (1999).
24. Mukherjee, S., Zha, X., Tabas, I. & Maxfield, F. R. Cholesterol distribution in living cells: fluorescence imaging using dehydroergosterol as a fluorescent cholesterol analog. *Biophys. J.* **75**, 1915–1925 (1998).
25. Schroeder, F., Butko, P., Nemezc, G. & Scallen, T. J. Interaction of fluorescent delta 5,7,9(11),22-ergostatrien-3 beta-ol with sterol carrier protein-2. *J. Biol. Chem.* **265**, 151–157 (1990).
26. de Saint-Jean, M. *et al.* Osh4p exchanges sterols for phosphatidylinositol 4-phosphate between lipid bilayers. *J. Cell Biol.* **195**, 965–978 (2011).
27. Blagovic, B., Rupcic, J., Mesaric, M. & Maric, V. Lipid analysis of the plasma membrane and mitochondria of brewer's yeast. *Folia Microbiol.* **50**, 24–30 (2005).
28. Ha, S. *et al.* Crystallization and preliminary X-ray crystallographic analysis of sterol transcription factor Upc2 from *Saccharomyces cerevisiae*. *Acta Crystallogr. Sect. F Struct. Biol. Cryst. Commun.* **69**, 147–152 (2013).
29. Flowers, S. A. *et al.* Gain-of-function mutations in UPC2 are a frequent cause of ERG11 upregulation in azole-resistant clinical isolates of *Candida albicans*. *Eukaryot. Cell* **11**, 1289–1299 (2012).
30. Huh, W. K. *et al.* Global analysis of protein localization in budding yeast. *Nature* **425**, 686–691 (2003).
31. Habeler, G. *et al.* YPLdb: the yeast protein localization database. *Nucleic Acids Res.* **30**, 80–83 (2002).
32. Marie, C., Leyde, S. & White, T. C. Cytoplasmic localization of sterol transcription factors Upc2p and Ecm22p in *S. cerevisiae*. *Fungal Genet. Biol.* **45**, 1430–1438 (2008).
33. Teste, M. A., Duquenne, M., Francois, J. M. & Parrou, J. L. Validation of reference genes for quantitative expression analysis by real-time RT-PCR in *Saccharomyces cerevisiae*. *BMC Mol. Biol.* **10**, 99 (2009).
34. Sasse, C. *et al.* The stepwise acquisition of fluconazole resistance mutations causes a gradual loss of fitness in *Candida albicans*. *Mol. Microbiol.* **86**, 539–556 (2012).
35. Akache, B. & Turcotte, B. New regulators of drug sensitivity in the family of yeast zinc cluster proteins. *J. Biol. Chem.* **277**, 21254–21260 (2002).
36. Shianna, K. V., Dotson, W. D., Tove, S. & Parks, L. W. Identification of a UPC2 homolog in *Saccharomyces cerevisiae* and its involvement in aerobic sterol uptake. *J. Bacteriol.* **183**, 830–834 (2001).
37. Krishna, S. S., Majumdar, I. & Grishin, N. V. Structural classification of zinc fingers: survey and summary. *Nucleic Acids Res.* **31**, 532–550 (2003).
38. Tamrazi, A., Carlson, K. E., Daniels, J. R., Hurth, K. M. & Katzenellenbogen, J. A. Estrogen receptor dimerization: ligand binding regulates dimer affinity and dimer dissociation rate. *Mol. Endocrinol.* **16**, 2706–2719 (2002).
39. MacPherson, S., Laroche, M. & Turcotte, B. A fungal family of transcriptional regulators: the zinc cluster proteins. *Microbiol. Mol. Biol. Rev.* **70**, 583–604 (2006).
40. Schjerling, P. & Holmberg, S. Comparative amino acid sequence analysis of the C6 zinc cluster family of transcriptional regulators. *Nucleic Acids Res.* **24**, 4599–4607 (1996).
41. Fernandez-Cid, A., Vega, M., Herrero, P. & Moreno, F. Yeast importin-beta is required for nuclear import of the Mig2 repressor. *BMC Cell Biol.* **13**, 31 (2012).
42. Echeverria, P. C. & Picard, D. Molecular chaperones, essential partners of steroid hormone receptors for activity and mobility. *Biochim. Biophys. Acta* **1803**, 641–649 (2010).
43. Lee, H. C., Hon, T. & Zhang, L. The molecular chaperone Hsp90 mediates heme activation of the yeast transcriptional activator Hap1. *J. Biol. Chem.* **277**, 7430–7437 (2002).
44. Picard, D. Chaperoning steroid hormone action. *Trends Endocrinol. Metab.* **17**, 229–235 (2006).
45. Diezmann, S., Michaut, M., Shapiro, R. S., Bader, G. D. & Cowen, L. E. Mapping the Hsp90 genetic interaction network in *Candida albicans* reveals environmental contingency and rewired circuitry. *PLoS Genet.* **8**, e1002562 (2012).
46. Van Hauwenhuyse, F., Fiori, A. & Van Dijk, P. Ascorbic acid inhibition of *Candida albicans* Hsp90-mediated morphogenesis occurs via the transcriptional regulator Upc2. *Eukaryot. Cell* **13**, 1278–1289 (2014).
47. Bard, M. *et al.* Sterol uptake in *Candida glabrata*: rescue of sterol auxotrophic strains. *Diagn. Microbiol. Infect. Dis.* **52**, 285–293 (2005).
48. Vasicek, E. M., Berkow, E. L., Flowers, S. A., Barker, K. S. & Rogers, P. D. UPC2 is universally essential for azole antifungal resistance in *Candida albicans*. *Eukaryot. Cell* **13**, 933–946 (2014).
49. Double, S. Preparation of selenomethionyl proteins for phase determination. *Methods Enzymol.* **276**, 523–530 (1997).
50. Terwilliger, T. C. & Berendzen, J. Evaluation of macromolecular electron-density map quality using the correlation of local r.m.s. density. *Acta Crystallogr. D Biol. Crystallogr.* **55**, 1872–1877 (1999).
51. Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. *Acta Crystallogr. D Biol. Crystallogr.* **66**, 486–501 (2010).
52. Brunger, A. T. *et al.* Crystallography & NMR system: A new software suite for macromolecular structure determination. *Acta Crystallogr. D Biol. Crystallogr.* **54**, 905–921 (1998).
53. Liu, R., Lu, P., Chu, J. W. & Sharom, F. J. Characterization of fluorescent sterol binding to purified human NPC1. *J. Biol. Chem.* **284**, 1840–1852 (2009).
54. Arthington-Skaggs, B. A., Jradi, H., Desai, T. & Morrison, C. J. Quantitation of ergosterol content: novel method for determination of fluconazole susceptibility of *Candida albicans*. *J. Clin. Microbiol.* **37**, 3332–3337 (1999).
55. Guarente, L. Yeast promoters and lacZ fusions designed to study expression of cloned genes in yeast. *Methods Enzymol.* **101**, 181–191 (1983).
56. McIntosh, A. L. *et al.* Fluorescence techniques using dehydroergosterol to study cholesterol trafficking. *Lipids* **43**, 1185–1208 (2008).

Acknowledgements

We are grateful to T.A. Leonard for discussions and for the editing of this manuscript. This project was supported by the National Research Foundation of Korea (NRF) grant funded by the Ministry of Education, Science and Technology (grant nos NRF-2010-0013448 and NRF-2014R1A1A1003060).

Author contributions

Y.J.I. and H.Y. designed the project; H.Y. and S.H. cloned the genes, purified and crystallized the recombinant proteins; H.Y., J.T. and S.H. performed the ligand-binding assays and yeast cell biology experiments; C.W.L. performed the HPLC and mass spectroscopy analyses; H.Y., S.H.E. and Y.J.I. collected and analysed the X-ray data; Y.J.I. carried out structure refinements; Y.J.I. wrote the manuscript. All authors discussed the results and approved the manuscript.

Additional information

Accession codes: Coordinates and structure factors for the reported crystal structure have been deposited in the Protein Data Bank with the accession code, 4N9N.

Supplementary Information accompanies this paper at <http://www.nature.com/naturecommunications>

Competing financial interests: The authors declare no competing financial interests.

Reprints and permission information is available online at <http://npg.nature.com/reprintsandpermissions/>

How to cite this article: Yang, H. *et al.* Structural mechanism of ergosterol regulation by fungal sterol transcription factor Upc2. *Nat. Commun.* 6:6129 doi: 10.1038/ncomms7129 (2015).